Inactive Instrument

Highlights Urovant Sciences Ltd.

Equities

UROV

BMG9381B1081

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Urovant Sciences and Pierre Fabre Médicament Enters into Exclusive License Agreement	05/07/22	CI
Urovant Sciences Ltd. Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting	15/05/22	CI
Urovant Sciences Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints	13/05/22	CI
Urovant Sciences Announces the Publication of A New, Post-Hoc Analysis of Data from the Phase 3 EMPOWUR Trial of GEMTESA 75 Mg in the International Journal of Clinical Practice	19/04/22	CI
Urovant Sciences to Present Key Data for GEMTESA® 75 Mg At the 2021 Annual Meeting of the American Urological Association	18/08/21	CI
Sumitovant Biopharma Ltd. completed the acquisition of the remaining 27.6% stake in Urovant Sciences Ltd..	28/03/21	CI
Urovant Sciences : Posts Wider Fiscal Q3 Net Loss	12/02/21	MT
Urovant Sciences Ltd. Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/02/21	CI
Urovant Sciences : Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results	12/02/21	BU
Urovant Sciences Announces Progression of URO-902 Phase 2A Trial Following Positive Recommendation from the Data and Safety Monitoring Board	11/02/21	CI
Urovant Sciences : Gets FDA Nod For Overactive Bladder Drug Gemtesa -- Stock Up 3% After-Hours	23/12/20	MT
Urovant Sciences Announces U.S. FDA Approval of GEMTESA 75 mg Tablets for the Treatment of Patients with Overactive Bladder	23/12/20	CI
Urovant Sciences Reports Topline Data from the Phase 2A Clinical Trial Evaluating Once-Daily Vibegron 75 Mg	24/11/20	CI
Urovant Sciences : Reports Positive Data From Study of Vibegron to Treat Overactive Bladder	19/11/20	MT
Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron Empowur Long Term Extension Study	19/11/20	CI
Disney, DraftKings, Palantir, Li Auto : What to Watch When the Stock Market Opens Today	13/11/20	DJ
Disney, DraftKings, Palantir, Li Auto : What to Watch When the Stock Market Opens Today	13/11/20	DJ
Disney, DraftKings, Palantir, Li Auto : What to Watch When the Stock Market Opens Today	13/11/20	DJ
Urovant Sciences : To Be Acquired by Sumitovant Biopharma for $16.25 Per Share; Stock Soars 91% in Late Trade	12/11/20	MT
Sumitovant Biopharma Ltd. entered into a definitive merger agreement to acquire remaining 27.6% stake in Urovant Sciences Ltd. for approximately $210 million.	11/11/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Urovant Sciences Ltd.

Equities

UROV

BMG9381B1081

Highlights

Filters